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Background: In 1976 Dr. John Wolfe introduced the relationship between breast tissue 
composition and breast cancer risk. Breast tissue composition is one of several well-
established risk factors for breast cancer, but is not currently incorporated into commonly 
used risk prediction models or routinely used in clinical practice to recommend for or 
against routine screening. Knowledge of risk factors and their predictive abilities is 
important for creating appropriate screening strategies. It would be of value if breast 
tissue composition, alone or in combination with other risk factors, would allow for 
creating personalized screening plans for every woman based on her individual risk as 
screening can be harmful and costly. 
 
Objective: To assess whether the American College of Radiology (ACR) Breast 
Imaging-Reporting and Data System (BI-RADS) breast tissue composition categorization 
has a sufficient degree of incremental value beyond age to predict incidence and/or 
breast cancer-related mortality in average-risk women aged 40 to 59. Evaluation is 
based on the following criteria: magnitude of risk estimates, discriminatory ability, net 
reclassification index, clinical utility and cost-effectiveness. 
 
Search methods: I searched PubMed and EMBASE from January 1, 2003 to April 19, 
2014. Radiologist assessment of breast tissue composition using mammography was 
the intervention of interest. I focused on outcomes assessed in the short-term, within 10 
years of intervention. I excluded lifetime estimates. Exclusion criteria for the population 
included risk factors, such as personal history of breast cancer and BRCA 1 or BRCA 2 




Main results: Eleven studies met the inclusion criteria. While exposure and outcome 
measurement were relatively consistent across studies, there was heterogeneity in study 
design, population age range, follow-up duration and outcomes assessed. Despite this, it 
is clear that there is a dose-response relationship between breast tissue composition 
and risk of in situ and invasive breast cancer. Across all of the studies, effect sizes were 
moderate. There was not a meaningful relationship with short-term mortality, though few 
studies in this review evaluated this outcome. The risk factor’s ability to discriminate, 
separate cases from non-cases, was close to chance and not clinically proven to be 
superior to existing Breast Cancer Risk Assessment Tool (Gail Model). There were no 
studies that calculated the Net Reclassification Index (NRI), or evaluated clinical utility or 
cost-effectiveness.  
 
Limitations of the evidence: The BI-RADS lexicon used to describe breast tissue 
composition is subjective; creating measurement bias that can lead to inaccurate risk 
estimates. Outcome data (incidence and vital status) were obtained from population-
based registries. Equal, valid and reliable measurement of the outcome rests on the 
completeness, validity and reporting timeliness of utilized databases. This information 
was variably reported and not easily obtainable. Lastly, breast density is not stable over 
time. Crossovers, movement from one category to another, can diminish risk estimates. 
 
Conclusion: Based on the available evidence, breast tissue composition, as currently 
assessed in routine clinical practice, does not fulfill the criteria to be valuable as a 
predictive tool. Authors of breast density notification laws should clarify intentions, 
critically examine the evidence and evaluate outcomes. Given subjectivity, focus could 
be shifted to objective measurements and other enterprising technologies, such as 





In his article “Sick individuals and sick populations”, well-known epidemiologist 
Geoffrey Rose writes that he encourages his medical students when thinking about their 
patients to consider – Why did this patient get this disease at this time?1 For many 
diseases, the answers to this multi-step question are not easy. Other pertinent questions 
for population level interventions include – What are the harms and benefits to 
intervening on this disease process? How much will it cost the patient and society? 
Currently, many organizations recommend routine screening mammography to women 
for early detection of breast cancer. Mammography has harmful downstream 
consequences for some women and is costing the United States progressively more 
money over time.2, 3 So, to decrease the undesirable outcomes of this screening 
intervention, we must go back to part of Rose’s question – Why this patient?  
Breast Cancer Facts  
According to the Surveillance, Epidemiology and End Results (SEER) annual 
Cancer Statistics Review, a report from a population-based registry that covers 28% of 
the general US population, breast cancer has the highest incidence of any cancer, about 
125 cases per 100,000 women. It is estimated that in 2014, 40,000 women will die of 
breast cancer. The highest proportion of breast cancer deaths occur in women aged 55 
to 64. About 5% of deaths occur in women aged 35 – 44, and 16% occur in women 
greater than 84-years-old.4 There is persistent controversy around screening 
recommendations for all women – young and old, “higher risk” and average risk, and 
with and without pertinent medical findings. While the conversation around breast cancer 
screening is fluid and polemic, participating stakeholders have the same interest in mind 
– to relieve the burden of breast cancer and to preserve the health and quality of life of 
women. The most reasonable screening recommendation for breast cancer is the result 
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of interpreting statistics, like those from the SEER database, and integrating these facts 
with population health concepts. 
 Health statistics include disease outcome and frequency data. Incidence, a 
frequency measure, refers to the number of new breast cancer cases among an initially 
disease free population over a specified time. Screening is the detection of disease in 
clinically asymptomatic individuals. The desired effect of screening mammography is to 
reduce breast cancer-related morbidity and mortality. Due to a number of factors, such 
as disease course and disease detection capabilities, early detection by screening can 
increase documented incidence.  
Ductal carcinoma in situ (DCIS) is classified as a breast cancer and thought by 
some to be a precursor to invasive breast cancer.5, 6 DCIS is a biologically 
heterogeneous disease, each variant having different prognoses. Unfortunately, at this 
time, we are not able to predict with certainty the DCIS lesions that will progress and 
those that will not. The incidence of DCIS has increased with the increased utilization of 
screening mammography.7 Low-grade DCIS is thought to be a slowly progressive lesion, 
thus introducing length-time bias and contributing to over-diagnosis. The early detection 
of DCIS is giving rise to the increased incidence of breast cancer. However, detecting 
these lesions that will not cause relevant outcomes by screening is not beneficial.  
Mortality, a prognostic health outcome, is a useful statistic to help balance this 
information. For example, a high incidence rate for a clinically benign condition, with a 
very low mortality rate is not distressing. Short-term mortality, at 5 or 10 years, is 
preferable to lifetime estimates because it reduces the risk of influence by competing 
comorbidities. To determine the effect of screening mammography, the incidence of both 
in situ and invasive breast cancer, and pertinent health outcomes, such as near-term 
mortality are helpful. These pieces of information, integrated with other concepts, can be 
used to determine at what age and how often a women should be screened.  
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Breast Cancer Risk Factors 
A risk factor is a characteristic, condition or behavior that makes an individual 
more likely to experience an outcome. Thus, risk factors are often used when predicting 
outcomes, such as invasive breast cancer diagnosis and breast cancer-related death. 
Risk factors can be causally related or statistically correlated to the outcome of interest. 
Support for causality can come from evidence of biologic mechanism or temporal 
sequence of events for example. Both causal and statistical risk factors may be useful in 
predicting breast cancer incidence and mortality.  
Risk factors for breast cancer include age, number of first-degree relatives with a 
history of breast cancer, having a first-degree relative with breast cancer before the age 
of 40 and having “extremely dense” breast tissue composition.8 In the United States, 
breast tissue composition is most commonly reported using standard language outlined 
by the American College of Radiology (ACR) in the breast imaging-reporting and data 
system (BI-RADS) Atlas®. Other commonly associated risk factors for primary breast 
cancer in all women include benign proliferative breast lesions, inherited genetic 
mutations, reproductive factors, such as age at menarche and nulliparity; and some 
lifestyle factors, such as alcohol use, smoking, decreased physical activity, and weight 





Table 1. Breast cancer risk according to risk factors8, 9 
Risk Factor Breast Cancer Risk 
Ratio (95% CI) 
Risk Factor Breast Cancer Risk 
Ratio (95% CI) 
Two first-degree 
relatives with breast 
cancer* 
3.84 (2.37 – 6.22) Menarche </= 12 
years of age* 
1.10 (0.98 – 1.23) 
First-degree relative 
diagnosed at <40 
years of age* 
3.0 (1.8 – 4.9)  Nulliparity* 1.16 (1.04 – 1.26) 
Extremely dense 
breast tissue* 
2.04 (1.84 – 2.26) Alcohol use >/= 
14 drinks per 
week* 
1.24 (0.87 – 1.78) 
Benign proliferative 
lesions 
 Smoking* 1.05 (0.98 – 1.13) 
  Weight gain of 
10.0 kg after 
menopause*** 
1.18 (1.03 – 1.35) 
*In women aged 40 to 49  
** Women less than 70 years of age  
***Post-menopausal women aged 30 to 55  
 
Breast Density and Legislation 
In 2008, a breast cancer survivor founded Are You Dense, Inc. and Are You 
Dense Advocacy, Incorporated, organizations whose mission is to raise breast density 
awareness. Her experience with self-reported, non-screen detected, advanced stage 
breast cancer was the impetus for organizational establishment. The advocates describe 
breast density as the “best kept secret”, referencing the inaction of the medical 
community.10, 11 Although breast density has long been recognized as one of the multiple 
risk factors for breast cancer and included in reports to physicians, its integration into 
clinical decision–making has been difficult and problematic. Despite some hesitance of 
health care professionals, patient advocates have helped to foster a legislative 
movement, encouraging action on both state and federal levels.   
As of July 2014, nineteen states have enacted breast density notification laws 
requiring radiologists to report breast density in routine patient summaries. The specific 
requirements outlined by the laws vary by state. Some require that lay patient 
! 7 
 
summaries inform all women about their breast composition while others require that 
only a subset be notified.12 In North Carolina, women who are categorized as 
“heterogeneously dense” or “extremely dense” must receive the following statement by 
law.  
 
“Your mammogram indicates that you may have dense breast tissue. Dense breast 
tissue is relatively common and is found in more than forty percent (40%) of women. The 
presence of dense tissue may make it more difficult to detect abnormalities in the breast 
and may be associated with an increased risk of breast cancer. We are providing this 
information to raise your awareness of this important factor and to encourage you to talk 
with your physician about this and other breast cancer risk factors. Together, you can 
decide which screening options are right for you. A report of your results was sent to 
your physician.”13 
 
Breast density notification regulations have also reached the federal arena. 
Congresswoman Rosa DeLauro of Connecticut introduced the Breast Density and 
Mammography Reporting Act of 2013 (H.R. 3404).14 This federal law would require 
reports to include whether a woman is at, above or below average breast cancer risk 
according to parenchymal pattern. In addition, the report would state that women with 
extremely dense breast tissue composition, about 10 percent of the general population, 
might benefit from supplemental screening. The most recent action was referral to the 
Subcommittee on Health.  
Breast Cancer Screening Recommendations 
Organizations, such as the US Preventive Services Task Force (USPSTF) and 
American Congress of Obstetricians and Gynecologist (ACOG), have taken differing 
courses of action in response to including breast density in guidance statements. In 
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2009, the USPSTF recommended regular, biennial screening mammography for women 
aged 50 to 74.15 They gave screening women aged 40 to 49 a Grade C 
recommendation, which means that it can be selectively offered based on professional 
judgments and patient preferences. In regards to breast density, they stated that it was 
unclear whether additional screening of women with dense breast tissue would reduce 
mortality. A need for better understanding of breast tumor biology that predisposes 
women to fast growing cancers and mortality was also noted.  
While the ACOG recommendation deviates from the USPSTF in that its 
screening recommendation starts at age 40, their approach to breast density is similar. 
In a recent Committee Opinion, crafted specifically to address management of women 
with dense breast tissue, ACOG recommended against any alternative or adjunctive 
tests, such as breast ultrasound, to screening mammography. Research needs are also 
highlighted since there is very limited data for supplementary screening.16  The American 
College of Radiology Imaging Network (ACRIN) sponsored a clinical trial investigating 
the diagnostic yield and diagnostic accuracy of combined mammography and ultrasound 
screening versus mammography alone in women with heterogeneously dense breast 
tissue in at least one quadrant. Investigators found that the addition of ultrasound to 
mammography would yield 1 to 7 more breast cancer diagnoses per 1000 women, but it 
would also substantially increase the rate of false positives. The false positive rate was 
about 10% percent for the combined approach and only 4% for mammography alone.17 
In summary, research gaps around breast density exist and efforts to add supplementary 
screening have demonstrated to be of poor overall benefit.  
The American College of Radiology (ACR) released a report in 2012 cautioning 
breast density description in lay patient summaries; however, they support provider 
notification. They highlight several important considerations. One, the assessment of 
breast density is not reliably reproducible among interpreting radiologists, which may 
! 9 
 
lead to confusion and the perception that mammography is an unreliable imaging 
technique. Second, it would lead to increased demand for supplemental imaging 
techniques, such as ultrasound (US) and magnetic resonance imaging (MRI). The 
utilization of these techniques may lead to more false positive test results and 
subsequent benign breast biopsies. Non-mammographic screening also has not been 
demonstrated to reduce mortality. Lastly, informing patients might create undue anxiety 
and worry about breast cancer risk.  
In this statement, the common tradeoffs associated with cancer screening are 
highlighted. On the benefit side, cancer screening reduces morbidity and mortality by 
detecting localized disease. On the harms side, screening is accompanied by false 
positive test results, over-diagnosis, over-treatment and associated psychological harms. 
While some advocacy groups and legislative bodies are ready to move forward with 
requiring actionable steps on the grounds of breast density, caution must be exercised 
as we explore what prevention strategy should be used based on epidemiology and 
scientific knowledge as screening is not without harm. The benefits of considering breast 
tissue composition in screening conditions are not clear. Its careless integration could 
increase the harms already noted.  
Screening Strategies 
Screening for breast cancer using mammography is an example of secondary 
prevention, detecting an asymptomatic “disease” state. Prevention can be further 
characterized as selective or population-based. In a selective prevention strategy, 
people at “higher risk”, on a continuum, than what is deemed acceptable are identified 
and targeted for intervention. In a population-based strategy, interventions are created to 
mitigate the determinants of incident disease in the general population and not just for 
certain individuals.1 High-risk screening strategies can be viewed on a spectrum from 
moderately selective to very selective. The recommendations from the USPSTF and 
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ACOG, for example are all high-risk screening strategies because they target women of 
a certain age. However, including risk factors other than age into intent-to-screen 
decision makes the strategy even more selective.  
Both risk-based and population-based strategies have advantages and 
disadvantages.  Advantages of targeting prevention to higher risk individuals are that 
there is a more favorable benefit-to-risk ratio in comparison to population-based 
strategies; it effectively and efficiently allocates limited resources providing cost-effective 
care and it motivates both patients and providers to participate. While risk-based 
strategies have their advantages, their applicability is limited by the ability to 
appropriately identify and demarcate the highly susceptible individuals from those at 
lower risk.  
Challenging aspects of risk-based prevention strategies are that some risk 
factors, such as breast density and age, are not stable over a lifetime. In addition, 
established cutoff values may exclude borderline patients who will actually go on to 
develop cancer. Lastly, identifying higher risk individuals alone, on the basis of breast 
density, is palliative and temporary in that it identifies those that may go on to develop 
breast cancer. There are strategies that go further to modify risk factors after 
identification. In this case, if breast density was found to be predictive of breast cancer 
outcomes, chemoprevention could be used to modify breast tissue, decreasing a 
woman’s susceptibility to the outcome.  
 Health care professionals and policymakers are tasked with selecting an 
appropriate strategy for breast cancer prevention. When selecting an approach, one 
should consider the “burden of suffering” and the “preventable burden”. The burden of 
suffering includes the population attributable risk proportion, the amount of disease 
attributable to a risk factor within a population, and heuristics and biases that influence 
patients’ risk perceptions.18 In this case, the population attributable risk proportion would 
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be the proportion of incident breast cancer cases or breast cancer-related mortality due 
to dense breasts. If this proportion were high, then a strategy that selects for this 
population would be helpful. A risk-based strategy is preferred over a population-based 
strategy when the “cases” are concentrated in a group of individuals with an identifiable 
risk factor. This concept is further demonstrated in Figure 1.  





In Figure 1b, all of the “cases” are concentrated in one sub-group D, while in Figure 1a; 
the “cases” are evenly distributed across the entire population.  A strategy that targets 
group D in Figure 1b. would be highly effective if the majority of “cases” were 
concentrated in that subgroup.  
 
The concept of preventable burden incorporates the screening strategy 
effectiveness, in this case mammography. While screening mammography has reduced 
breast cancer mortality over the years, it is not without limitations.15, 19, 20 Welch and 
Passow sought to quantify the benefits and harms of mammography screening to help 
women make decisions about whether to be screened or not screened.21 In their study, 
they focused on women in three different age groups: 40 to 49, 50 to 59 and 60 to 69 
years of age. They quantified the following outcomes: number of breast cancer-related 
deaths, number of false-positive recalls, number of false positive biopsy 












A B C D 
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used in the model because of common clinical practice though conflicting with USPSTF 
recommended screening strategy.15, 21 They found that as age increases more women 
will avoid dying from breast cancer and fewer will undergo biopsies because of a false 
positive recall. Young women are more often faced with screening harms. One could 
infer from this study that using an age-based risk strategy in a certain age subgroup to 
target mammography would relieve the burden of suffering – fewer women would die 
and fewer would undergo burdensome biopsies. Using age alone to target screening is 
not perfect. Some women younger than the USPSTF recommended screening age of 50 
will develop life-threatening advanced stage breast cancer. One of the challenges for 
prevention is uncovering the ideal combination of risk factors that can be used to target 
interventions.  
In addition to harms, the cost of screening mammography creates a moment of 
pause. In the US, actual screening practice of women aged 40 to 85 years old costs 
approximately 7.8 billion dollars per year.22 O’Donaghue et al. developed models of 
various screening strategies to estimate the actual cost of screening in 2010 and to 
compare it to existing screening recommendations. The USPSTF screening strategy, 
which included biennial screening for women 50 to 74 years of age, personalized 
screening of high-risk women aged 40 to 49 and screening for women 75 to 85 years old 
with few comorbidities; costs less than actual practice. The estimated cost was 3.5 
billions dollars per year. The authors highlight that the Patient Protection and Affordable 
Care Act of 2010 (ACA) is likely to increase screening mammography rates, which 
further emphasizes the need to curtail spending and be more cost-conscious, spending 
finite financial resources on necessary and beneficial health care.  
Potential for Breast Density  
A high-risk screening strategy would be a desirable approach to breast cancer 
screening because it is cost-effective, efficient and would relieve the burden of suffering 
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while minimizing harm to the low-risk, general population. It would be valuable if breast 
density would allow for the narrowing of our focus on a smaller population to screen at 
regular intervals or a personalized plan for every woman based on the risk she carries. 
There are several relevant questions – Would targeted screening of individuals with 
dense breast tissue relieve the burden of suffering? At what interval and with what 
imaging modality, should a 42-year-old woman with ‘extremely dense’ breast tissue be 
screened? Should a 52-year-old woman with less dense, ‘almost entirely fatty’ breast 
tissue composition be screened at all? These are complex questions, but the first step is 
discerning the ability of breast density to discriminate between women who will and will 
not be diagnosed with breast cancer. This review compares the predictive ability of 
breast tissue composition to age to evaluate whether it adds incremental value to cancer 




 In this section, I will provide the background information necessary to interpret 
the findings and significance of this systematic review. If breast tissue composition is 
used as a method to target higher risk individuals for screening, we must understand 
how breast density is determined and how to evaluate risk factors as predictive tools.  
History of Mammographic Breast Density 
 A mammogram is an x-ray image of the breast. Breast connective and epithelial 
tissues attenuate x-rays creating a radio-opaque image. This is in contrast to adipose 
tissue, which appears radiolucent on mammogram. Mammographic breast density refers 
to the characteristics the opaque areas. Dr. John Wolfe was the first to introduce the 
relationship between breast parenchymal patterns and subsequent incident cancer.23 In 
a prospective cohort of 5284 women 30 years or older with a median follow-up time of 
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2.5 years, he found that there was a positive linear relationship between mammographic 
breast density and breast cancer risk. He divided breast parenchymal patterns into four 
categories: N1, P1, P2 and DY. The N1 pattern was considered “normal”. He did, 
however, note that normal varied with age. He stated that in younger women, the 
mammogram would appear trabeculated because connective tissue transverses the fatty 
breast. In older women, normal would be almost completely fat. DY denotes the most 
dense parenchymal pattern. Women classified as N1 had a breast cancer incidence 
lower than those classified as DY. 
Since this study, several investigators have published findigns demonstrating a 
similar relationship.24 However, the biologic mechanism linking mammographic breast 
density to increased breast cancer risk isn’t completely resolved. Masking bias, the 
concealing of non-calcified lesions by dense breast tissue, is part of the story. Boyd et al 
in three nested case-control studies, found that the mammographic breast density and 
risk for breast cancer persisted regardless of whether the cancer was screen detected or 
identified by other means.25 This demonstrates that there are likely other pathways other 
than screening failure to explain the relationship.   
Mammography Quality Standards Act and Program 
 The Mammography Quality Standards Act of 1992 authorizes the Food and Drug 
Administration (FDA), under its regulation of radiation-emitting products, to ensure that 
facilities perform high-quality mammograms. The MQSA recognizes the ACR as an 
accrediting body and thus supports their standard mammography reporting 
recommendations.26 The 5th edition of the BI-RADS Atlas provides standards for 
reporting results of breast mammography, magnetic resonance imaging (MRI) and 
ultrasound (US). The BI-RADS lexicon was created after widespread use of screening 
mammography accentuated marked variability in radiation dose, image quality and 
processing speed.27 Also of issue were diagnostic inconsistencies and reporting.19 The 
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resource establishes terminology, report organization, classification systems and 
assessment and management recommendations. The specifications are important for 
patient satisfaction, clinical decision-making, outcome monitoring and quality assurance. 
 A mammography report must include the indication, description of breast 
composition, important findings, statement of comparison to previous examinations, final 
assessment and management recommendation. There are seven final assessment 
categories, ranging from “Category 0: Incomplete” to “Category 6: Know Biopsy-Proven 
Malignancy”. Each assessment category is linked to a management recommendation 
and a statement of likelihood of cancer. For example, a “Category 4A: Low suspicion for 
malignancy” has a 2 to 10% likelihood of malignancy and tissue diagnosis is 
recommended. While the BI-RADS lexicon has been in practice for over 20 years, the 
breast composition categorization was added in 2002.  
There are four breast composition categories, which are listed in Table 2. The 
most recent, fifth, edition of the BI-RADS Atlas published in 2013 deviates from previous 
editions in that the organization abandoned quartile ranges for percentage dense tissue. 
The Committee on BI-RADS wanted to emphasize the text descriptions of density, as 
they are clinically more important than percentage dense area when considering the 
sensitivity of mammography. Dense breast tissue that masks non-calcified lesions is 
more meaningful than a relatively less dense tissue that occupies a larger area. There 
are other qualitative and quantitative assessments of breast density. Other qualitative 
assessments include Wolfe’s parenchymal patterns, and Tabar and Boyd classifications. 
The qualitative assessments are subjective, relying on the interpreting radiologist. 
Quantitative, computer-assisted measurements include percentage mammographic 
density based on digitized images, and volumetric measurements. While quantitative 
assessment software is more objective, it is expensive technology with few models that 
are readily, commercially available.  
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 While the BI-RADS lexicon is useful in standardizing reporting, it does have 
limitations. Given that the breast composition categories are qualitatively assessed and 
assigned independently by radiologist, there is limited inter-observer agreement.28 There 
is substantial agreement between repeat breast density assessments by the same 
radiologist using the BI-RADS lexicon (κ: 0.72 95% CI: 0.66 – 0.78).29, 30 Moderate to low 
agreement is noted between radiologists interpreting screening mammography images. 
Agreement at the extremes of breast composition, “almost entirely fat” and “extremely 
dense” is also higher. This is unfortunate given that the middle categories, “scattered 
fibroglandular densities” and “heterogeneously dense” make up the highest proportion of 
breast composition in the general population, Table 1. 
Table 2. Breast tissue composition categories and frequency distribution31 
Breast Composition Categories Percent of General 
Population 
a. The breasts are almost entirely fatty 10% 
b. There are scattered areas of fibroglandular density 40% 
c. The breasts are heterogeneously dense, which may 
obscure small masses 
40% 
d. The breasts are extremely dense, which lowers the 
sensitivity of mammography 
10% 
 
Risk Factors as Predictive Tools 
 In medicine, clinicians gather evidence to estimate risk, disease likelihood, and 
prognosis. Evidence comes from sources, such as patient anecdote, medical history, 
physical exam and diagnostic test results. Predictive tools in practice integrate the truth; 
observed disease outcomes, with the biological and environmental factors that give rise 
to disease into statistical models. Prediction is important to both prevention and 
treatment, and allows for intervention targeting to higher risk individuals and avoiding 
harm to those likely to receive little benefit.  
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 Cancer risk prediction models in breast cancer include known risk factors for the 
outcome. Risk factors that are most suitable for prediction models are those that have a 
strong association and exhibit a dose-response relationship with the outcome.32 Risk 
factors that reflect determinism based on pathophysiology rather than the factor 
preceding the outcome, or temporal determinism, are preferred.33 Chosen risk factors 
are strongly associated and often exhibit a dose-response relationship with the outcome.  
Existing breast cancer prediction models have incorporated some of these risk 
factors. The Breast Cancer Risk Assessment Tool, also known as the Gail Model, 
incorporates personal history of breast cancer or radiation to the chest, genetic history, 
age, age at menarche, age at first live birth of child, number of first-degree relatives that 
have had breast cancer, personal history of breast biopsies and notable results, and 
race/ethnicity. Studies have also explored adding breast density to the prediction model, 
more specifically, assessing whether its addition adds incremental value.  
Predictive ability moves far beyond the strength of association and relationship 
characterization. A good prediction model is internally valid, produces the right answers 
for the source population, provides clinically important discrimination and is 
generalizable. The key aspects used to evaluate predictive tools are the magnitude and 
certainty of risk score, discrimination, calibration, and net reclassification. The criteria 
and their definitions are outlined in Table 2.33-36 The actual use of a prediction tool in 
everyday practice is contingent on its clinical utility and cost-effectiveness, also defined 
in Table 2. The incremental value that a risk factor adds to an existing model is based on 
all of these factors.  
 Evaluating all facets of predictive ability is necessary to minimize harm and to 
make output data easily interpretable. In addition, one must be mindful that risk factors 
have their limitations as prognostic tools. For example, to see meaningful, incremental 
change in discrimination, very large measures of association are required. To easily 
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create cutoffs, the distribution of breast cancer in those with and without dense breast 
tissue needs to be sufficiently separated. The deleterious BRCA1 and BRCA2 mutations 
that cause hereditary breast and ovarian cancer are examples of risk factors associated 
with substantial risk.15, 37 It would be valuable to identify risk factors or a combination of 
risk factors that would amount to a very strong association with breast cancer incidence 
and/or mortality.  
Table 3. Criteria for evaluating prediction tools 
Criterion Description 
Calibration The ability of a tool to accurately predict the observed risk level, 
whether the predict outcome is equal to the observed outcome. 
The statistical test that is used to assess for calibration is the 
Hosmer-Lemeshow X2 test.  
Clinical utility  In a setting of efficacious uptake and implementation, clinical 
utility refers to the ability of a screening test to prevent adverse 
health outcomes. This concept integrates implementation science. 
Discrimination The probability that a randomly selected patient who develops 
breast cancer (“a case”) will have a higher risk score than a 
randomly selected non-case. It is described using the 
concordance (c) statistic and ranges from 0.5 to 1.0. In a model 
that discriminates well, there is little overlap between cases and 
non-cases. A c statistic of 1.0 indicates perfect discrimination.  
Incremental cost-
effectiveness 
The incremental difference in costs and health outcomes between 
an intervention and an alternative that competes for the same 
resources. The cost is multi-factorial and can included program 
and productivity costs for example.   
Net Reclassification 
Improvement 
Reclassification refers to a change in risk category that leads to a 
new action or end to an old action. Net reclassification 
improvement would be the appropriate movement of one risk 
category to another. The movement of a “case” to a higher risk 
stratum would be appropriate, while movement down an 
inappropriate or poor reclassification. Net Reclassification 
Improvement (NRI) is the sum of the difference in proportions of 
cases moving up minus those moving down, and the proportion of 
non-cases moving down minus those moving up.  






In this review, I assessed whether the ACR BI-RADS breast composition 
categorization had ability as a predictive tool. Specifically, whether it had superior ability 
over age to predict incidence and/or breast cancer-related mortality in average-risk 
women aged 40 to 59. The following key questions guided the review. Table 3 contains 
a PICOTSS table with inclusion and exclusion criteria. 
(1) What are the age-adjusted relative risk and/or odds ratio of in situ and/or invasive 
breast cancer according to breast tissue composition category? How does that 
risk compare to age alone? 
(2) How many incident cancers per 100,000 women ages 40 to 49 are diagnosed 
within 5 or 10 years of indexed mammogram?  
(3) How many incident cancers per 100,000 women ages 50 to 59 are diagnosed 
within 5 or 10 years of indexed mammogram?  
(4) Does breast composition categorization offer clear advantage in discriminatory 
power over age alone? 
(5) Using the risk estimate for an average-risk 50-year-old woman as the threshold, 
does age-adjusted or age-specific breast composition lead to net reclassification 
improvement? 
(6) What is the clinical utility of BI-RADS breast composition categories as a breast 
cancer predictive tool? 
(7) Is it cost-effective to screen women ages 40 to 49 with “heterogeneously dense” 





Table 4. PICOTSS description for systematic review  
 Inclusion Criteria Exclusion Criteria 
Population Average-risk women aged 40 to 
59.  
Men; women with a personal 
history of in situ or invasive breast 
cancer, chest irradiation, benign 
proliferative changes, atypia or 
breast augmentation; first-degree 
family history of breast cancer; 
BRCA 1 and BRCA 2 mutation 
carriers; women less than 40 and 
greater than 60 years of age 
Intervention Breast tissue composition as 
assessed by a radiologist using 
film or digital mammography and 
described using ACR BI-RADS 
breast tissue composition 
categories 
Breast density as assessed by 
other imaging technologies, such 
as MRI or ultrasound, and 
automated or computer-assisted 
methodologies; quantitative 
measurements of breast density, 
such as percentage dense area 
and percentage non-dense area.  
Comparison Age as a predictive tool  Risk predictions based on the 
following risk factors alone or in 
combination: first-degree family 
history, reproductive factors: parity, 
age at menarche, menopausal 
status and age at menopause; 
BMI, benign breast pathology, 
bone mineral density and lifestyle 
factors: alcohol consumption and 
smoking history  
Outcome ! Measures of effect: absolute 
risk, risk ratio or odds ratio 
! Number of incident in situ 
and/or invasive breast cancer 
cases within 5 years and/or 10 
years per 100,000 women 
! Breast-cancer related mortality 
within 10 years of indexed 
mammogram 
! Lifetime risk  
! Incidence 10 years after 
indexed mammogram. 
! Mortality 10 years after indexed 
mammogram and/or mortality 
due to causes other than 
breast cancer.  
Time for 
outcome  
10 years After 10 years 
Literature 
Search 














The target population for this systematic review was women aged 40 to 59 given 
the proximity to screening age and heterogeneity in breast tissue composition. Men were 
excluded from this review, as well as, other high-risk groups, such as those with a 
personal history of breast cancer, a history of chest irradiation, a significant first-degree 
family history of breast cancer and BRCA 1 and BRCA 2 mutation carriers. These high-
risk populations were excluded from the review because prevention strategies will be 
different than those implemented for the general population.  
There are several methods of assessing breast tissue composition to include 
subjective assessments by radiologist, objective computerized assessments that 
estimate the percentage of dense area of the total area, volumetric measurements and 
other computer-assisted methodologies. Currently, automated methods are an active 
area of research given the need for equal, valid and reliable measurements that remove 
the subjectivity of the radiologist. For this review, I focused on the BI-RADS reporting 
system given its widespread and routine use in the US. I excluded computerized and 
automated methods of breast density measurement because they are in limited use at 
the population level currently.  
The outcomes of interest included effect measures, such as the risk ratio (RR) 
and odds ratio (OR), absolute risk increase above age-specific risk and breast-cancer 
related mortality. The number of incident in situ and/or invasive breast cancers with 5 or 
10 years of indexed mammogram was another desired outcome. I wanted to quantify the 
number of cancers per 100,00 women ages 40 to 49, before they reach the USPSTF 
recommended screening age of 50 years old. In those that older than 50, I wanted to 
investigate how their risk changed after taking into account their breast tissue 
composition. I excluded lifetime risk, and incidence and mortality after 10 years to focus 
on 10-year outcomes that might influence current guidelines and screening decision-
making. In comparison to cumulative risk estimates calculated in the short-term, 
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competing risk can confound the relationship between exposure and lifetime risk 
estimate.  
The literature search begins in 2003 when the ACR published its fourth edition of 
BI-RADS Atlas. Prior editions used quartile ranges for subjective amount of dense breast 
tissue that was observed on mammogram. This edition included text descriptors, such 
as ‘almost entirely fat’ or ‘extremely dense’. The Committee on BI-RADS made this 
decision because they acknowledged that the breast tissue composition’s masking 
ability, causing a reduction in the sensitivity of mammography, was clinically more 
important than the amount of area covered.   
The study designs of interest include cohort studies, case-control studies, 
modeling studies, systematic reviews, randomized controlled trials and meta-analysis. 
Cross-sectional were not included in this review given that by design they lack 
longitudinal data. Case reports and case series have been excluded because they are 
low in the hierarchy of research design.  
Data Sources and Search Strategy 
I searched PubMed and EMBASE from January 1, 2003 to April 19, 2014 to 
identify potentially relevant articles to address the key questions. For PubMed, I used a 
combination of MeSH terms and keywords to capture relevant literature. I did not apply 
limits to the search so that recent, non-indexed articles would not be excluded. I adapted 
the search strategy for PubMed for utilization in EMBASE. For all of the articles that met 
eligibility criteria for full-text review, I hand searched reference lists to identify missed 
articles and to corroborate the initial search strategy. I consulted two research librarians 
to formulate the most appropriate search strategy. Appendix A contained the detailed 




 I reviewed titles and abstracts that were retrieved from the initial online search to 
determine whether an article was admissible based on inclusion and exclusion criteria. I 
then reviewed the full-text of the articles to determine final eligibility for inclusion in 
systematic review. For this paper, I alone reviewed articles to determine eligibility.  
Data Collection and Quality Assessment 
 For all of the articles that met the eligibility criteria, I extracted pertinent data and 
assessed each study’s quality. Dual review was not utilized for this paper given time and 
resource limitations. I used a common template to extract data from articles. Data of 
interest included study design, registry source, sample size, study population age range 
and effect measures. Effect measures included odds ratios, relative risks and hazard 
ratios.  
 To evaluate individual studies’ internal validity, I used a list of quality criteria, 
adapted from the USPSTF Procedure Manual for each type of included study design. 
For the cohort studies, internal validity was assessed based on methodology of selecting 
participants, the comparability of selected groups, whether there was important 
differential loss to follow-up, their explanation and measurement of both the exposure 
and outcome.  For case-control studies, internal validity was based on the methodology 
of identifying cases and selecting controls and whether investigators paid appropriate 
attention to potential confounding variables. For systematic reviews and meta-analyses, 
I paid attention to whether the search strategy and study selection was comprehensive 
and systematic, whether appraisal of the individual studies included a quality 
assessment and, lastly, if in their conclusion, they elaborate on both the certainty and 
magnitude of the conclusion after evidence synthesis. For each study, I made a 
subjective, overall assessment of the risk of bias taking into account all of the 
aforementioned factors and assigned a rating of good, fair or poor for internal and 
external validity.  
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Data Synthesis and Analysis 
 After assessing the quality of individual studies, I qualitatively synthesized the 
results. I did not use quantitative statistical methods because of time and resource 
limitations. The USPSTF Procedure Manual was referenced again to guide the 
assessment of strength of the overall body of evidence. To evaluate the evidence, 
important considerations were the hierarchy of research design, the quantity of good 
quality studies, generalizability to the U.S. primary care setting, number of study 
subjects` and consistency of results. Based on these factors, I assigned a subjective 
rating of convincing, adequate, or inadequate to the entire body of evidence. Biases that 
affect the cumulative evidence, such as publication bias and selective reporting, were 
also considered.  
 
Results 
 The search strategy identified 544 unduplicated references. I excluded articles 
after reviewing titles and abstracts if they did not meet the eligibility criteria. Common 
reasons for exclusion included not including target population, using quantitative 
measurements, such as percentage dense area, to measure breast density, usig 
computerized and/or automated tools to measure breast density, using imaging 
technologies other than film or digital mammography and simply not being relevant to 
key questions. I selected 25 articles for full-text review and excluded conference 
abstracts and studies using quantitative measurements. Eleven articles remained for 
inclusion in this systematic review. Appendix B contains a flow chart documenting the 
process from initial search strategy to inclusion in the systematic review.  
The study designs included prospective cohort studies, case-control studies, a 
nested case-control study, two modeling studies and a meta-analysis The age range 
captured by the data was 25 years and older. A minority of studies used an upper age 
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limit for exclusion. Some studies used subgroup analysis, calculating outcomes for 
specific age ranges within overall study population. Others used menopausal status to 
stratify results. The frequency distribution of breast tissue composition in all of the 
studies mirrored that of the general population.  
The measurement of the exposure, BI-RADS breast tissue composition, was 
similar across the majority of the studies. The majority of the studies used breast density 
assessments that were performed in routine clinical practice across the various radiology 
facilities using the ACR BI-RADS lexicon despite the recognized problems with observer 
agreement. One study utilized one observer and another study utilized double blind 
readings. The application of the BI-RADS lexicon is inherently not equally applied or 
reliable because it is subjective. There were some differences across the studies in 
which mammography report was used if more than one mammography report was 
available. Some studies included the first mammogram documented in the study period, 
while others used the mammogram closest to the diagnosis. The majority of studies 
included only breast density assessments associated with screening mammograms, 
while a minority included assessments from diagnostic mammograms. Investigator 
obtained information related to patient’s medial history by self-report using 
questionnaires. The relevant health history was similar across all studies and included 
age at birth of first child, age at menarche, first-degree family history of breast cancer, 
menopausal status, use of hormone replacement and personal history of breast cancer, 
biopsy or augmentation.  
The majority of studies included DCIS and invasive breast cancers together as 
the outcome, while a minority focused on invasive cancer alone (N=3) or DCIS (N=1) 
alone. There was also variation in whether investigators used only screen-detected 
cancers or a composite of screen-detected and interval-cancers. The duration of follow-
up after indexed mammogram ranged from 1 to 8 years.  
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A common feature of all included studies was cancer registry utilization to obtain 
outcome data. The cancer registries included hospital-based registries and purportedly 
population-based registries. Only one study, the Mayo Mammography Health Study, 
used a hospital-based registry. The population-based registries included state tumor 
registries, SEER and some or all of the registry sites within the Breast Cancer 
Surveillance Consortium (BCSC). The BCSC, a program of the National Cancer 
Institutes Division of Cancer Control and Population Sciences, was established in the 
early 1990s. There are seven BCSC sites – Carolina Mammography Registry, New 
Hampshire Mammography Network, Vermont Breast Caner Surveillance System, 
Colorado Mammography Project, Group Health, San Francisco Mammography Registry 
and New Mexico Mammography Project. The BCSC registry sites collect mammography 
examination data from radiology facilities, medical history from patient questionnaires 
and cancer outcomes data from state tumor registries, SEER and pathology facilities.  
I was not able to easily obtain information about the geographic catchment areas 
and baseline characteristics for each site, however, information about the BCSC overall 
was available. Between 1994 and 2009, the BCSC collected data from 296 radiology 
facilities across their seven sites. More than 90% of these facilities were associated with 
academic medical centers. Using 2000 census data to compare BCSC counties to all 
other US counties, women living in BCSC catchment counties had a higher median 
family income, had a higher proportion of individuals with high school degrees and had a 
lower proportion of Hispanics and Blacks.38 The number of participating radiology 
facilities and their catchment area varies in each state. Few of the studies included in 
this systematic review provided details about the proportion of the state population 
captured by the registry, baseline characteristics of captured population in comparison to 
others in the geographic area and the registries quality; quality being evaluated by the 
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completeness of the data, the timeliness of outcome reporting and the accuracy of 
recorded data.  
The majority of studies also used a passive methodology for obtaining follow-up, 
using only databases to obtain cancer incidence and mortality data. Only one study used 
active follow-up, attempting to contact patients by mail or telephone, to confirm cancer or 
cancer-free status, vital status or movement outside of registry catchment area.  
The overall body of evidence was convincing, but many of the studies had fair 
internal and external validity, and lack of precision of estimates in women with ‘extremely 
dense’ breast tissue composition. Risk of bias was present due to the the use of a 
subjective measure for exposure, passive follow-up methods for outcome assessment 
and use of registry sites whose individual quality cannot be easily ascertained. There 
was substantial heterogeneity in the age of women included and whether subgroup 
analysis. Therefore, it is difficult to make conclusions about the estimates for women 
aged 40 to 59. Some studies include age subgroups, demarcated at different intervals, 
and others divide population according to menopausal status.  
The key questions addressed by the literature were those related to age-adjusted 
risk of breast cancer according to breast density and discriminatory ability. There were 
no studies that addressed net reclassification ability, clinical utility and cost-effectiveness 
of screening on the grounds of BI-RADS breast tissue composition. The risk estimates 
were small-to-moderate in magnitude and exhibited a consistent dose-response gradient 
from ‘almost entirely fat’ to ‘extremely dense’. In all of the studies, women with 
‘extremely dense’ breast tissue composition represented one of the smallest samples in 
the overall study population creating less precise estimates, which was indicated by 
wider confidence intervals. There was also heterogeneity in how studies grouped 
exposure status, some combining ‘heterogeneously dense’ with ‘extremely dense’ for 
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example leading to over-estimation or under-estimation of effect for women in different 
breast tissue composition categories.  
In the studies that calculated a c-statistic, the value was around 0.6, slightly 
above the value of chance, 0.5. One study reported that this value was statistically 
significant and greater than that of the Breast Cancer Risk Assessment Tool. They did 
not prove clinical signification, however. Appendix C, Tables 1 – 22 contains data 
extraction and appraisal of each individual study.  
Gierach et al. 201239 
 The study aim was to evaluate the relationship between mammographic breast 
density and risk of breast cancer-related death. The study participants were from five of 
the seven BCSC sites, chosen because they routinely collecting body mass index (BMI) 
data. The study only included women who were diagnosed with primary invasive cancer. 
The majority of the population was non-Hispanic, White and post-menopausal (74.6%). 
The average age was 59. The mean-follow-up time from index mammogram to 
diagnosis was about 7 years. In this study, high mammographic breast density was not 
associated with breast cancer-related death. In their fully adjusted model, the hazard 
ratio of breast cancer-related death in those with ‘extremely dense’ breast tissue 
composition was 0.92 (95% CI: 0.71 – 1.19) when compared those with ‘scattered 
fibroglandular densities’. Women with ‘almost entirely fat’ breast tissue composition 
actually had a higher risk of death; the hazard ratio was 1.36 (95% CI: 1.04 – 1.77). BMI 
modified the relationship between breast density and death. The authors hypothesize 
that risk factors for breast cancer-related death may not be the same as those 
influencing the development of breast cancer.  
The internal validity of this study is threatened by small sample size, 
measurement bias and inappropriate attention to important confounders. State vital 
records and cancer registries were used to measure vital status. The use of death 
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certificates is subject to ascertainment bias as physicians commonly confuse underlying 
case of death with the mechanism of death.40 There is no detail about how the cause of 
death is documented in these sources, and the accuracy and timeliness of the reporting. 
In addition, participants were assumed alive if there was no documentation of death in 
these sources. There could have been more deaths than what was documented. Other 
potential confounders that should have been measured include comorbidity and other 
socioeconomic variables, such as race, education and health insurance status. This 
study received a poor rating for internal and external validity.  
Kerlikowske et al. 200741 
 The study objective was to determine whether a change in mammographic 
breast density over time was associated with breast cancer risk. The stated rationale for 
this study was based on knowledge that breast density is modifiable and changes over 
time. Specifically, breast density changes with age, body mass index (BMI), menopause 
and other reproductive factors. Given that exposure of interest was change in density 
over time, study participants had to have at least two screening mammograms at least 9 
months apart. The median time between screening examinations was 3.2 years. For this 
systematic review, only breast density measurements and outcomes associated with first 
screening mammography were extracted. In addition, in the stratified analysis by age, 
only outcomes associated with stable breast density measurements were extracted so 
that systematic review results would be consistent.  
Cancer outcomes included both invasive and in situ breast cancers, but the 
majority of cancers (80%) were invasive. In women with ‘extremely dense’ breast tissue 
composition documented on the first screening mammogram, the odds ratio of in situ 
invasive breast cancer was 1.75 (95% CI: 1.52 – 2.00) as compared to those with 
“scattered fibroglandular densities’. For women with “almost entirely fat” composition the 
odds ratio was 0.63 (95% CI: 0.54 – 0.74). An increase in breast density over time was 
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associated with a higher breast cancer risk in women with “almost entirely fat’, ‘scattered 
fibroglandular densities’ and ‘heterogeneously dense’ breast density as compared to 
those with assessments that remained unchanged. For example, a woman with ‘almost 
entirely fat’ on first screen and ‘scattered fibroglandular densities’ on last screen had an 
adjusted rate of breast cancer per 1000 women of 9.9 (95% CI: 6.4 – 15.5).  
This study was rated as having good internal validity and fair external validity. An 
aspect of their methods that is unique is adjustment for misclassification of breast tissue 
composition using the Reade-Christopher and Kupper method. Statistical analysis was 
performed with and without adjustment for misclassification. Given that results were 
unchanged, final reported vales were actually unadjusted. The external validity was 
limited for reasons similar to others in this study, demographics and inclusion of 
radiology facilities affiliated with academic medical centers. 
Kerlikowske et al. 201042 
 Kerlikowske et al. aimed to report whether the association between breast tissue 
composition and breast cancer risk and severity differed according to menopausal status 
and post-menopausal hormone use. The average age of the study population was 56 
years old. They found that the magnitude of the association between ‘extremely dense’ 
breast tissue and breast cancer risk was stronger in pre-menopausal women. For 
women classified as having ‘extremely dense’ breasts, the hazard ratio (HR) of breast 
cancer was 2.04 (95% CI: 1.84 – 2.25) using ‘scattered fibroglandular densities’ as the 
referent category. The 5-year risk of breast cancer for a pre-menopausal woman 
between the ages of 45 and 59 was estimated to be 2.1 (95% CI: 1.9 to 2.2). There was 
not a meaningful change in magnitude of association according to menopausal status for 
women with almost entirely fat breast tissue composition. Breast cancer risk in post-
menopausal women with almost entirely fatty breasts was less than the referent 
category (HR = 0.57, 95% CI: 0.53, 0.62). The authors conclude that women with low 
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breast density have a low breast cancer risk regardless of age, menopausal status or 
post-menopausal hormone use. The management of the covariate BMI threatens the 
validity of the study. In their statistical analysis, the average BMI for the entire population 
was incorporated. The estimates may be inaccurate for women of different weight 
classes. One of the study’s strengths is the large sample size, as they pooled data from 
all of the existing BCSC sites.  
MacKenzie et al. 200743 
 In this study, investigators examined the association between breast tissue 
compositions and risk of ductal carcinoma in situ (DCIS). The outcome DCIS is a 
heterogeneous disease, but was not further characterized as low-grade or high-grade for 
example. The rationale for this study was that there was little prior evidence examining 
this relationship, the majority of prior literature focusing solely on invasive breast cancer. 
In this prospective cohort study, following about 155,000 women in New Hampshire and 
Vermont over an average follow-up time of about 4 years, the relative risk (RR) of DCIS 
in pre-menopausal women with ‘extremely dense’ breast tissue was 2.4 (95% CI, 1.47 – 
3.91) relative to women with ‘scattered fibroglandular density’ breast tissue composition. 
The relationship was not as strong in post-menopausal women (RR = 1.49, 95% CI: 0.93 
– 2.37).   
Olson et al. 201244 
 The Mayo Mammography Health Study (MMHS) was a study whose goal was to 
identify mammographic features that can be used to identify women at higher risk for 
breast cancer. The MMHS was a prospective cohort enrolling women from three states – 
Minnesota, Iowa and Wisconsin. In a nested case-control study, investigators sought to 
determine whether acquisition parameters were associated with mammographic density 
and whether the parameters confounded the relationship between breast density and 
incident breast cancer. The mammogram acquisition technique parameters included x-
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ray tube voltage peak, milliampere-seconds, thickness and compression force. The 
rationale for studying mammogram acquisition parameters was that the majority of prior 
studies of breast density and breast cancer risk have been conducted across multiple 
institutions using different image acquisition techniques. The relationship between 
mammographic breast density and breast cancer was confirmed. Women with extremely 
dense breast were about 3-times as likely to develop breast cancer than those with 
almost entirely fat (HR 2.96, 95% CI: 1.73 – 5.07). The studied acquisition parameters 
alone and in combination did not confound this relationship, as there was little to no 
change in calculated hazard ratios.  
Tesic et al. 45 
 Tesic et al highlight that breast density varies by ethnicity and geography and 
use this as the justification for conducting this study in Croatia. The study aim was to 
determine whether the relationship between breast density and breast cancer risk held in 
a non-Western population. The Zagreb Breast Cancer Surveillance population-based 
registry in Croatia captures 22% of the population registry. The participating facilities 
include university hospitals, outpatient clinics and mobile mammography units. The 
study population consisted of post-menopausal women aged 50 to 69 with no personal 
history of breast cancer or breast augmentation. The majority of the study population 
(87%) had ‘almost entirely fat’ or ‘scattered fibroglandular densities’ breast tissue 
composition. Unique to this study, the exposure, breast tissue composition, was 
assessed by radiologist in routine practice using double blind readings. There was 
substantial intra-observer agreement and moderate inter-observer agreement. The 
absolute number of breast cancers diagnosed was highest in women with ‘scattered 
fibroglandular densities’. For analysis, investigators combined women with 
‘heterogeneously dense’ and ‘extremely dense’ breast composition. Women in this group 
in situ and invasive breast cancer risk estimates higher than women classified as having 
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‘scattered fibroglandular densities’ (Odds ratio 1.9 (95% CI: 1.3 – 2.7). Per report, the 
risk estimate did not change substantially after adjusting for relevant covariates.  
Tice et al. 200546 
 In this study, Tice et al. sought to determine if the addition of breast density to the 
Gail model had better predictive accuracy than the Gail model alone. The study 
population was small relative to other studies in this review (N = 81,777). The 
investigators only included women from the San Francisco Mammography Registry. 
They found that the addition of breast density to the model significantly increased model 
fit. There wasn’t must difference in the c-statistics however. The new model slightly 
increased the c-statistic, calculated to be 0.68 (95% CI: 0.66 – 0.7). The value for the 
existing Gail model is 0.67. A study strength that stands out in comparison to the other 
studies included in the review is the composition of the cohort. The cohort was racially 
and ethnically diverse. This makes the results more generalizable. Another factor that 
increases its external validity is the variety among the radiology facilities that participate 
in this registry site. The facilities include hospital-based clinic, private practices and a 
mobile mammography unit. Only one of the facilities is affiliated with an academic 
medical center, this stands out as overall most of the BCSC sites are affiliated with 
academic institutions. 
Tice et al 200847 
 This study expanded on the previous work by Tice et al. in 2005 that tested the 
accuracy of a new prediction model. In this study, using a larger population of women, 
they developed and validated a risk assessment tool that incorporates breast density. 
The two other risk factors that were incorporated as yes or no categorical variables were 
history of breast cancer in first-degree relative and history of breast biopsy. The model 
was well calibrated. The expected rate of invasive breast cancer according to the model 
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was 1.41%. The observed rate was 1.38%. Discrimination was statistically significant 
slightly better than that of the Gail model (c-statistic 0.660, 95% CI: 0.651 – 0.669).  
Vacek et al. 200448  
 The study aim was simple, to ascertain the breast cancer risk among women in 
different breast tissue composition categories. The study included only one of the 
registry sites in the BCSC, the Vermont Breast Cancer Surveillance System. This 
registry site collects outcome information from Vermont and New Hampshire to account 
for the fact that some VT residents actually receive health care in NH. This method 
reduces selection bias, increasing the proportion of individuals for which follow-up 
information is available. Unique to this study only, in comparison to others included in 
this review, is confirmation of breast cancer-free status. They did not assume that the 
absence of cancer documentation indicated that the patient did not have breast cancer. 
They reviewed results of exit mammograms and biopsies to check for disease. If neither 
of these resources were available, participants were excluded. The frequency 
distribution of breast tissue composition of the excluded women did not differ greatly 
from those include in the study. Relative to ‘almost entirely fat’ breast tissue, pre-
menopausal women with ‘extremely dense’ breast tissue had an increased risk of 
invasive breast cancer (Risk ratio (RR) 4.6 (95% CI: 1.7 – 12.6).  
Zhang et al. 201249 
 This study was conducted using data from the Carolina Mammography Registry. 
The objective was to examine the relationship between breast tissue composition and 
breast cancer-related mortality according to age, race and cancer stage. Unique to this 
study design was the combination of breast tissue composition categories into smaller 
groups. Women with ‘almost entirely fat’ and ‘scattered fibroglandular densities’ breast 
tissue were combined into one group and the remaining in another. They found that 
there was no statistical difference in mortality for either group after adjusting for pertinent 
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covariates. The internal validity is threatened by loss to follow-up. The study is also not 
applicable to the general population as it was restricted to women of certain racial and 
ethnic groups.  
There was one meta-analysis that was identified in the search and was a 
commonly found in the reference lists of included studies.24 This article was ultimately 
excluded from the review because it included studies utilizing quantitative measures and 
also captured some of the literature already included in this review. This meta-analysis 
incorporated studies that utilized both quantitative and subjective breast tissue 
composition assessments. The qualitative measures included the Wolfe classification, 
BI-RADS lexicon and Tabar classification. The quantitative measure included 
percentage breast density. The association between breast density and breast cancer 
risk was stronger using the quantitative measurement of breast density. Only 3 studies 
included in this analysis used the BI-RADS lexicon. In two of the studies, ‘scattered 
fibroglandular densities’ breast tissue composition was used as the referent category. 
The combined risk ratio of breast cancer was 4.08 for women with ‘extremely dense’ 
breast tissue. The meta-analysis only included literature published up to November 
2005, threatening the validity of the conclusions for present day practice. The authors 
conduct a comprehensive literature search, but do not use organized, standard criteria 
for appraising included studies.  
 
Discussion 
The objective of this systematic review was to determine whether the ACR BI-
RADS breast tissue classification system could be used as a predictive tool to identify 
women between the ages of 40 and 59 who are at a higher risk for early primary incident 
breast cancer and/or mortality. The value and ability as a predictive tool is based on 
fulfilling the following criteria: magnitude of risk estimates, discriminatory ability, net 
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reclassification index, clinical utility and cost-effectiveness. The identification of strong 
risk factors that can be used in risk prediction is an important goal because screening 
interventions can be targeted to populations more likely to develop the majority of breast 
cancer cases, thus minimizing harm to lower risk women and controlling health care 
cost.  
Significance of main findings  
After the search strategy, one finding that was notable was that most of the 
studies evaluating breast density and its relationship to breast cancer risk use 
quantitative measures, such as percentage dense area, rather than the routinely used 
BI-RADS lexicon to assess breast tissue composition. In research conceptual 
frameworks, effectiveness research concerns the results that are achieved in actual 
practice while efficacy research is performed under ideal conditions. The use of 
computerized or automated quantitative measures are objective and reproducible, an 
ideal condition. Unfortunately, radiologists in clinically practice do not use these 
measurements routinely; instead, they are implemented under research environments. 
Given that the BI-RADS lexicon is used in actual practice, studies that utilize this 
measurement are more important in determining the effectiveness of this practice in day-
to-day operations. While quantitative measures are scientifically sound and may offer 
stronger effect measures, its utility is limited if not routinely used. If more research is 
done evaluating this relationship, methods used in routine practice should be studied or 
efforts to make affordable, objective measurement tools available to the general 
population should be initiated.  
Another finding was that the literature only addressed a few of the criteria used to 
evaluate risk factors as predictive tools. Specifically, the majority of studies calculated 
risk and a minority calculated the c-statistic for discriminatory ability. There were no 
studies that calculated the Net Reclassification Index (NRI). Due to these failures, 
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clinical utility and cost-effectiveness of a personalized screening intervention based on 
breast tissue composition could not be assessed. The only conclusion that can be stated 
with certainty about the data retrieved for this review is that there is a dose-response 
relationship between breast tissue composition and incidence of both in situ and invasive 
breast cancers. Discrimination was close to chance and almost equivalent to what the 
existing Gail model provides. This value is likely created because breast density, even 
the ‘extremely dense’ category, is not a strong enough risk factor. In addition, the 
prevalence of ‘scattered fibroglandular densities’ and ‘heterogeneously dense’ breast 
tissue compositions are prevalent in the population, capturing the majority of women. 
There is no evidence of a significant effect on short-term mortality, though few studies in 
this review evaluated mortality as an outcome and their internal validity was poor.  
While the measurement of exposure and outcome were relatively consistent 
across studies, there is significant heterogeneity in age group studied and duration of 
follow-up time. Therefore, the magnitude of the effect and at what time point it becomes 
strong or clinically significant cannot be concluded with certainty for the population of 
interest.  
Limitations of review 
 This systematic review is limited because I was the sole reviewer who assessed 
eligibility for inclusion. Dual-review is the preferred methodology. I also relied completely 
on published literature. There were conference abstracts without subsequent published 
manuscripts that I identified in my search. I did not attempt to contact study investigators 
due to time and resource limitations. Lastly, I qualitatively synthesized the results instead 
of pooling data in a meta-analysis. Meta-analyses are useful in increasing power and 
precision of estimates.  
Limitations of evidence 
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 Significant limitations of the evidence are the inherent bias in measurement of 
the exposure and the outcome, small body of literature using BI-RADS lexicon, few 
quality studies and heterogeneity of study design. The breast tissue composition is 
assessed using a subjective ordinal scale. The radiologist categorizes a women’s breast 
tissue composition based on how it appears on imaging using narrative guidance 
outlines in BI-RADS atlas.  
Using the BI-RADS lexicon, exposure can be misclassified. Observer agreement 
is less when considering women who fall into the two intermediate breast tissue 
composition categories, ‘scattered fibroglandular densities’ and ‘heterogeneously dense’, 
rather than at the extremes. For the two intermediate categories in comparison to the 
extremes, misclassification is differential, occurring more frequently in the intermediate 
categories. This misclassification has the potential to over or under-estimate the effect. 
In the majority of studies included in this review, ‘scattered fibroglandular densities’ was 
used as the referent category. Depending on the amount and direction of the 
misclassification, the effect of density on risk in women with ‘extremely dense’ breast 
could be different than what was measured. Using this subjective measure moving 
forward, the only way to reduce misclassification would be training radiologist to improve 
observer agreement.  
 Breast tissue composition is also not stable over time. The included studies had 
different durations of follow-up and most used exposure measurement obtained with the 
index mammogram. Migration bias, when study subjects more from one exposure 
category to another, can be inherently produced. Crossovers can diminish risk 
estimates. Using a one-time measurement to predict what happens 5 or 10 years out, 
after the potential influence of weight, age and hormones on breast density, may not be 
producing the most accurate results.  
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 Issues with measurement bias are also apparent in outcome assessment. The 
quality of cancer registries is assessed by its completeness, validity, timeliness and 
resemblance to the general population. The validity of outcome measurement rest on the 
accuracy of the population-based registries used. For this paper, I used web-available 
information about the BCSC and their respective sites. I did not contact the organization 
for more details, which may have been helpful to answering pertinent questions about he 
quality of registry data. I was not able to find important details, such as whether they 
used active or passive follow-up to contact physicians or patients, completeness of data 
and timeliness of outcome reporting.  
While the BI-RADS classification scheme and cancer registries represent the 
most feasible resources for research, there are improvements that can be made to 
improve the quality of the overall body of evidence. There is so much heterogeneity in 
study design, specifically, in the baseline characteristics of study subjects, follow-up time 
and outcomes of interest, that meta-analysis is likely not even possible.   
Implications for practice and research  
Breast density does not provide the information needed to determine for what 
population of women health care professionals and policymakers should recommended 
or dissuade from undergoing screening mammography. Given the problems associated 
with measurement, the focus could be shifted away from the BI-RADS lexicon to 
objective breast density measurements or away from mammography to other 
enterprising imaging technologies such as breast magnetic resonance imaging (MRI) or 
3D digital breast tomosynthesis. The findings of this review also suggest that we have 
reached the limitations of screening for breast cancer with mammography and may need 
to shirt our focus to lifestyle modifications, such as diet and exercise.50  
Another option for future research is to focus on the breast microenvironment, 
developing a better understanding of what leads to the differences seen on imaging. Sun 
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et al., in a population-based Polish Women’s Breast Cancer Study, studied the gene 
expression profile of high mammographic breast density. They found that 
mammographic density reflects transcriptional and signaling changes at the molecular 
level.51 Using data from the Carolina Breast Cancer Study (CBCS) and Carolina 
Mammography Registry (CMR), Razzaghi and Troester et al. have done research 
evaluating molecular features, or micro-environement, under different circumstances, 
following surgical wounds, with variable mammographic density patterns, and in women 
of different ages.52-54 The breast microenvironment may offer more valuable and 
predictive information than subjective imaging assessments. One priority would be to 
determine whether mammographic breast density reflects differences in the 
microenvironment. A proposed research agenda would select participants with normal 
breast tissue, but classified differently according to breast tissue composition. It would 
more ethically sound to select participants who have undergone breast biopsy with 
benign findings. The intervention would be to profile gene expression and with the 
outcome of describing features, looking for patterns. This may reveal a new biomarker 
with more predictive promise.  
 
Conclusion 
 Rose encourages considering – Why did this patient get this disease at this time? 
Why do average-risk women in between the ages of 40 and 59 get breast cancer at any 
given time? Unfortunately, there is no clear answer to this question because there is 
substantial uncertainty given scientific limitations. Strong risk factors, however, can have 
predictive value. So even if we do not have the answer to Rose’s question, we can use 
risk factors that are casually or statistically related to provide estimates of risk. These 
estimates of risk are incorporated into the weighing of benefits and harms when making 
population level decisions. While breast tissue composition has been a well-established 
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risk factor for some time, the evidence does not suggest that the ACR BI-RADS lexicon 
has predictive ability. The classification scheme does not discriminate well, which means 
that it is not clear at which breast tissue composition one is very likely to become a 
“case”. Without meeting this basic requirement of predictive ability, clinical utility and 
cost-effectiveness have no place. There is a clear, reproducible dose-response 
relationship between breast density and breast cancer, but more research is needed. In 
addition, continuous development of population-based registries held to high-quality 
standards should be encouraged. Policymakers and health care professionals should 
approach decisions around breast tissue composition with caution, as the evidence is 
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Appendix A: Detailed search terms 
PubMed:  
((((breast OR breast cancers OR breast cancer OR breast tumor OR breast tumors OR 
breast carcinoma OR breast neoplasm OR breast neoplasms) AND (mortality OR 
survival OR incidence OR prevalence OR risk OR risk factor OR risk assessment) AND 
(age OR breast density OR mammographic breast density OR mammographic density) 
AND (mammography OR mammogram) AND (mass screening OR screen OR screening 
OR screened) NOT (BRCA*) AND (BIRAD OR bi-rad OR bi rad OR BIRADs OR breast 
imaging-reporting and data system OR dense OR "extremely dense breast*" OR 
"heterogeneously dense" OR "fatty" OR "almost entirely fat" OR "scattered" OR 
"fibroglandular")))) 
EMBASE: 
'breast' OR 'breast'/exp OR breast OR 'breast cancer'/exp OR 'breast cancer' OR 'breast 
cancers' OR 'breast tumor'/exp OR 'breast tumor' OR 'breast tumors' OR 'breast 
carcinoma'/exp OR 'breast carcinoma' OR 'breast neoplasm' OR 'breast neoplasms'/exp 
OR 'breast neoplasms' AND ('mortality' OR 'mortality'/exp OR mortality OR 'survival' OR 
'survival'/exp OR survival OR 'incidence' OR 'incidence'/exp OR incidence OR 
'prevalence' OR 'prevalence'/exp OR prevalence OR 'risk' OR 'risk'/exp OR risk OR 'risk 
factor'/exp OR 'risk factor' OR 'risk factors'/exp OR 'risk factors' OR 'risk 
assessment'/exp OR 'risk assessment') AND ('age' OR 'age'/exp OR age OR 'density' 
OR 'density'/exp OR density OR 'breast density' OR 'mammographic density' OR 
'mammographic breast density') AND (mammogram OR 'mammography' OR 
'mammography'/exp OR mammography) AND (birad OR 'bi rad' OR 'breast imaging 
reporting and data system' OR 'extremely dense breast' OR 'heterogenously dense' OR 
'fatty' OR 'almost entirely fat' OR 'scattered' OR 'fibroglandular' OR 'dense') AND 
[female]/lim AND [english]/lim AND [2000-2014]/py 
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Appendix B: Flow diagram for search strategy  
  
362 records identified through 
PubMed searching 
450 records identified through 
EMBASE searching
268 duplicates removed 
544 titles and abstracts 
screened for eligibility 
25 full-text articles assessed 
for eligibility 
519 records excluded 
Reasons for exclusion included 
lack of focus on target population, 
use of quantitative breast density 
tools (ex. percent dense area or 
absolute dense area), use of 
automated and/or computerized 
tools and use of technology other 
than mammogram (ex. US or MRI) 
 
11 articles included in 
qualitative synthesis 
14 records excluded 
Reasons for exclusion included 
lack of published manuscript for 
abstract, outcome not of interest 



























Appendix C. Data extraction and critical appraisal of eligible studies  
 




Prospective cohort  
 
Sample size for analysis 9232 
Registry Five Breast Cancer Surveillance 
Consortium mammography registries: 
Group Health Cooperative in Washington 
State, the New Hampshire Mammography 
Network, the New Mexico Mammography 
Project, the San Francisco Mammography 




30 years or older 
Dates of 
Recruitment 
1996 – 2005 Average follow-up time 6.6 years 
 
Breast Tissue Composition Simple adjusted hazard ratio of 
invasive breast cancer death (95% CI) 
Adjusted for registry site, age at 
diagnosis, year of diagnosis and BMI 
Fully adjusted hazard ratio of invasive breast 
cancer death (95% CI) 
Adjusted for registry site, age at diagnosis, year 
of diagnosis and BMI, mode of detection, 
treatment and median family income 
Almost entirely fat 1.24 (1.03 – 1.74) 1.36 (1.04 – 1.77) 
Scattered fibroglandular densities Referent Referent 
Heterogeneously dense 1.01 (0.87 – 1.18) 1.07 (0.92 – 1.25) 
Extremely dense 0.91 (0.71 – 1.18) 0.92 (0.71 – 1.19) 









Selection: The authors identified all women 30 years and older that had been diagnosed with cancer 
(N = 26,571). They then selected subjects with breast density assessments and at least three years 
of follow-up. Subjects were excluded for low BMI and missing data. Within the text, there are no 
details about selection of radiology facilities and their resemblance to respective catchment area.  
Comparability of groups: Women with dense breast were younger, had lower BMI’s, etc.  
Follow-up: If state vital records were complete and no breast cancer related death information was 
available subjects were presumed to be alive. Given this methodology, follow-up vital status was 







Exposure: One of the exposures was the recorded ACR BI-RADS breast tissue composition 
assessment routinely used by radiologists in clinical practice. The ordinal scale is inherently 
unequally applied and unreliable due to its subjectivity. Index mammogram was defined as an exam 
within 5 years of diagnosis. If there were multiple exams, they used exam closest to diagnosis. If no 
screening mammogram was available, they used diagnostic mammogram results. Mammogram 
reports within 30 days after diagnosis were used in neither of the prior were available. Breast cancer 
data was retrieved from SEER, state tumor registries and/or pathology databases. 
Outcome: Vital status (alive or dead) and cause of death was obtained from cancer registries and 
state vital records. Completeness of records varied by database. A participant was assumed to be 





Confounding Variables potentially confounding the relationship between breast density and breast cancer related 
death include age, overall health status, stage of diagnosis, etc. There was no attempt to assess for 




Analysis The fully adjusted survival models were included pertinent covariates. Notably, authors did not 





There are inherent issues with passive follow-up methodologies for obtaining vital status information. 




The majority of the study population was White, non-Hispanic.  Poor  
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Prospective cohort  
 
Sample size for analysis 301,955 
Registry Seven BCSC mammography registries, which included the San 
Francisco Mammography Registry, Group Health’s Breast 
Cancer Surveillance, Colorado Mammography Advocacy 
Project, Vermont Breast Cancer Surveillance System, New 
Hampshire Mammography Network, Carolina Mammography 
Registry, and New Mexico Mammography Registry 
Age range 
Average 
30 years or older 
Dates of 
Recruitment 
1993 – 2003  Average follow-up time 3 year 
Results for the entire study population 
Breast Tissue Composition at 
first screen 
Number of invasive and in situ breast 
cancers per 1000 women 
OR for breast cancer (95% CI) 
Adjusted for age at last screening 
mammogram 
Almost Entirely Fat 5.0 (4.0 – 5.4) 0.63 (0.54 – 0.74)  
Scattered fibroglandular densities 7.0 (6.8 – 7.8) Referent 
Heterogeneously dense 10.0 (8.9 – 10.3) 1.32 (1.21 – 1.44) 
Extremely dense 13.0 (11.1 – 14.3) 1.75 (1.52 – 2.00) 
 Number of invasive and in situ breast 
cancers per 1000 women < 50 years old 
with no change in density 
Number of in situ and invasive breast 
cancer per 1000 women < 50 years 
old with no change in density 
Almost Entirely Fat 0.4 (0.2 – 7.7) 4.0 (3.1 – 5.2) 
Scattered fibroglandular densities 3.0 (2.6 – 3.6) 9.0 (8.5 – 10.0) 
Heterogeneously dense 6.0 (5.3 – 6.6) 12.0 (10.9 – 13.4) 










Selection: To be eligible for inclusion, participants had to have at least two screening 
mammograms with density assessment that were more than 9 months apart. This criterion 
selects for individuals that have access to regular care. Exclusion criteria included history of 
breast cancer or augmentation, and postmenopausal women on hormone replacement therapy. 
Comparability of groups: Women 70 years or older were more likely to be assigned to ‘almost 
entirely fat’ breast tissue composition group.  
Follow-up: There were no methods detailed for confirming cancer-free status, such as mail 






Exposure: Investigators used ACR BI-RADS breast tissue composition assessment routinely 
used by radiologists in clinical practice. The ordinal scale is inherently unequally applied and 
unreliable due to its subjectivity. If a woman had more than two screening mammograms during 
the study period, they used the earliest and last breast density assessments. 
Outcome: Invasive and ductal carcinoma in situ breast cancers identified using pathology 
database, SEER database and state tumor registries. Measurement included breast cancer 





Confounding Investigators adjusted rates and odds ratios for age at last screening mammogram, registry site 




Analysis They used logistic regression adjusted for registry, time between two screening mammograms, 
and age. “Scattered fibroglandular densities’ was used as the referent group. They were no able 
to adjust for body mass index (BMI) and age at first birth. They adjusted for misclassification of 





Missing values limited investigators in adjusting for pertinent covariates, specifically BMI.  Fair/good  
External 
Validity  
They pooled resources from all of the existing BCSC registry sites. The majority of BCSC 
radiology facilities are associated with academic medical centers. There were appropriate 








Prospective cohort  Sample size 
for analysis 
587,369 
Registry Seven BCSC mammography registries, which included the San 
Francisco Mammography Registry, Group Health’s Breast 
Cancer Surveillance, Colorado Mammography Advocacy 
Project, Vermont Breast Cancer Surveillance System, New 
Hampshire Mammography Network, Carolina Mammography 












5-year risk of in situ or invasive breast cancer 
(95% CI) 
5-year risk of in situ or invasive breast cancer 
(95% CI) 
 Pre-menopausal women Post-menopausal women 
Almost entirely fat 40 – 44 
45 – 49  
50 – 54  
0.4 (0.2 – 0.5)  
0.7 (0.5 – 0.9)  
0.8 (0.4 – 1.1)  
45 – 49  
50 – 54 
55 – 59  
0.5 (0.2 – 0.7) 
0.6 (0.5 – 0.8) 
0.8 (0.6 – 0.9) 
Scattered fibroglandular 
densities 
40 – 44 
45 – 49  
50 – 54 
0.9 (0.8 – 0.9)  
1.3 (1.2 – 1.4)  
1.5 (1.4 – 1.7)  
45 – 49  
50 – 54 
55 – 59 
0.8 (0.7 – 1.0) 
1.3 (1.2 – 1.4) 
1.7 (1.6 – 1.8) 
Heterogeneously dense 40 – 44 
45 – 49  
50 – 54 
1.5 (1.4 – 1.6)  
2.1 (1.9 – 2.2) 
2.3 (2.1 – 2.5)  
45 – 49  
50 – 54 
55 – 59 
1.6 (1.3 – 1.8) 
1.8 (1.6 – 1.9) 
2.4 (2.3 – 2.6) 
Extremely dense 40 – 44 
45 – 49  
50 – 54 
1.8 (1.7 – 2.0) 
2.5 (2.3 – 2.7) 
3.1 (2.7 – 3.5)  
45 – 49  
50 – 54 
55 – 59 
2.2 (1.6 – 2.7) 
2.2 (1.8 – 2.6) 









Selection: All women that had screening mammograms during specified time were initially 
selected. About 20% of the population was excluded because of missing data, specifically, body 
mass index (BMI), hormone use and menopausal status.  
Comparability of groups: They did not provide baseline characteristics of highlight differences in 
participants organized according to breast composition category. Instead, characteristics are 
given for the overall population.  
Follow-up: The BCSC registries had a cancer ascertainment rate of about 94% during this time. 
There are no details for how this rate is calculated, however.  
Medium 
potential for 
selection bias  
Measurement 
Bias 
Exposure: Investigators used ACR BI-RADS breast tissue composition assessment routinely 
used by radiologists in clinical practice. The ordinal scale is inherently unequally applied and 
unreliable due to its subjectivity. It is unclear which mammogram was used if there were multiple 
recording in the registry within the study time.  
Outcome: BCSC registries link to SEER and state tumor registries. Pathology databases were 





Confounding There was appropriate attention to the following covariates: hormone therapy use, menopausal 
status and age. BMI was a missing variable. BMI is a potential confounder of the relationship 




Analysis Adjusted 5-year breast cancer risk was calculated using partly conditional Cox proportional 







Authors do pay attention to issues of follow-up by documenting the cancer ascertainment rate, 





Consistent with the demographic characteristics of BCSC overall, the majority of the study 
population was White, concerning given that breast density thought to vary by race/ethnicity. 
Using an average BMI, which was also within normal range and not resembling US population, 










Prospective cohort Sample size for analysis 154,936 
Registry New Hampshire and Vermont Breast Cancer 
Surveillance System 
Age range 
Median age  




1994 – 2001  Average follow-up time 4 years 
 
Breast Tissue Composition Risk Ratio of DCIS (95% CI) 
Adjusted for age 
Risk Ratio of DCIS (95% CI) 
Adjusted for age 
 Premenopausal Postmenopausal 
Almost entirely fat 0.26 (0.03 – 1.95) 0.56 (0.36 – 0.90) 
Scattered fibroglandular density Referent Referent  
Heterogeneously dense 2.22 (1.51 – 3.28) 1.48 (1.18 – 1.86) 









Selection: Investigators identified women who had mammograms documented in the NH and VT 
registries. About 80% of the mammography facilities in NH and 16 centers total in VT participate 
in the BCSC. In NH, the majority of the mammographic facilities include hospitals (58%). The 
minority (18%) are physicians’ private offices. In VT, 88% of the facilities are hospitals.  
Comparability of groups: They did not provide baseline characteristics of highlight differences in 
participants organized according to breast composition category. Instead, characteristics are 
given for the overall population.  
Follow-up: The outcome was presence or absence of DCIS and information was sought from 
registries. Confirmation of disease-free status with passive or active procedures not 
documented. If no cancer diagnosis documented, participant assumed to be cancer free. Given 
this methodology, outcomes were available for all study participants creating no lost to follow-up. 
Medium 
potential for 
selection bias  
Measurement 
Bias 
Exposure: Investigators used the ACR BI-RADS breast tissue composition assessment routinely 
used by radiologists in clinical practice. The ordinal scale is inherently unequally applied and 
unreliable due to its subjectivity.  
Outcome: Breast cancer data was retrieved from participating pathology laboratories and 
supplemented with state tumor registries. They used systematized nomenclature of medicine 





Confounding For pre-menopausal women, investigators accounted for age, parity, BMI and family history. In 
post-menopausal women, they adjusted for hormonal therapy in addition to the prior.  
Appropriate 
attention 
Analysis They used Cox proportional hazards model with age as the time-scale. Censoring occurred at 
the time of diagnosis of in situ or invasive breast cancer diagnosis, and at the end of the study 





DCIS presents more issues for measurement bias. DCIS if often diagnosed with screening 
mammogram by the presence of micro-calcifications. Not all DCIS is associated with micro-




The majority of the study population had college-educated and White. The majority of the 








Nested case-control Sample size for analysis 2,259 
Source 
Population 
Minnesota, Iowa, Wisconsin  Age range 
Average 
35 years or older 
Dates  Recruitment – 2003 to 2006 
Outcome – 2010  
Average follow-up time  2.4 years  
 
Breast Tissue Composition HR of incident in situ and invasive 
breast cancer (95% CI) 
HR for incident in situ and invasive 
breast cancer (95% CI) 
Almost entirely fat Referent Referent 
Scattered fibroglandular densities 1.61 (1.13 – 2.29) 1.61 (1.11 – 2.33) 
Heterogeneously dense 2.02 (1.38 – 2.95) 1.96 (1.30 – 2.98) 
Extremely dense 2.96 (1.73 – 5.07)  2.56 (1.38 – 4.75)  
 Adjusted for age, menopausal status, 
body mass index, and 
postmenopausal hormones 














Selection: Eligibility criteria included having received screening Mammography at the Mayo Clinic, 
being 35 years or older, residing of Minnesota, Iowa, or Wisconsin (tri-state); and having no 
personal history of breast cancer. The eligible women were mailed an invitation packet. The cases 
included all incident breast cancer cases in the prospective cohort during the follow-up period. The 
control group was formed by randomly selecting 10% of overall cohort.  
Comparability of groups: They did not provide baseline characteristics of highlight differences in 
participants organized according to breast composition category.  
Follow-up: Study investigators used a combination of active and passive follow-up to obtain cancer 
outcomes. The active follow-up to obtain cancer and vital status included a mailed questionnaire or 
a telephone call. Active follow-up was successful in 83.1% of participants in 2009 and 78.4% of 







Exposure: Investigators used the ACR BI-RADS breast tissue composition assessment routinely 
used by radiologists in clinical practice. The ordinal scale is inherently unequally applied and 
unreliable due to its subjectivity  





Confounding The cases were older and a higher proportion reported former post-menopausal hormone use and 
post-menopausal status. Some baseline characteristics of interest, such as socioeconomic status 




Analysis For residents of the tri-state area censoring occurred at diagnosis, death and study end. For non-
residents, censoring occurred at diagnosis, last response to follow-up, last contact with Mayo Clinic 
and date last known to reside in area. The Cox proportional hazards model, using age at the time 
scale, was used to calculate hazard ratios. The C-statistic was also calculated to measure the 










Some of the issues that affect external validity include the trial setting, exposure, selection of 








Case-control Sample size for analysis Cases = 491 
Controls = 528 
Registry Carolina Mammography Registry (CMR), 
part of BCSC 
Age range 
Average 
20 – 74  
Dates of 
Recruitment 
1996 - 2001 Time from selection/diagnosis 




 No. of in situ and 
invasive breast cancer 
diagnoses in the cases 
No. of in situ and invasive 
breast cancer diagnoses 
in the controls 
OR (95% CI) 
*Adjusted for matching 
factors age and race 
Fat 13 25 0.5 (0.2 – 1.0) 
Scattered 183 197 Referent  
Heterogeneous  232 253 1.0 (0.7 – 1.3) 












Selection: Eligible study participants had mammography results recorded in the CMR and were 
participants in the CBCS. The participants were recruited from 24 counties in North Carolina. 
The response rate to recruitment efforts differed between cases (76%) and controls (55%). Both 
cases and controls had to attend an in-person interview. Controls were identified using drivers’ 
license and Medicare beneficiary lists.  
Comparability of groups: They did not provide baseline characteristics of highlight differences in 
participants organized according to breast composition category. Instead, characteristics are 
given for the overall population.  
Follow-up: There were no methods detailed for confirming cancer-free status, such as mail 






Exposure: Breast density measurements came from reports recorded in the registry. For cases, 
screening or diagnostic mammogram reports within 5 years prior to diagnosis and up to one year 
were accepted. For controls, screening mammogram reports up to 5 years prior and 3 years 
after selection data were accepted. Reading radiologist varied by site and was not blinded to 
patient medical history. Thus measurement was equal in that it was applied the same in both 
cases and controls. The measurement is neither valid nor reliable.  





Confounding A higher proportion of the women diagnosed with breast cancer had a family history of breast 
cancer, started menarche before the age of 13, and were nulliparous. The cases and controls 




Analysis Cases and controls were matched based on age and race. Logistic regression used to estimate 





Without more recruitment procedure details, it is unclear how both the selected cases and 
controls compare to the general population and to each other in their ability to experience the 




Study participants came from a limited number of counties in NC and explicit details of 





Table 13. Data Extraction Table for Tesic et al. 201345 
 
Study Design Prospective cohort  Sample size for analysis 52,752 
Registry Zagreb Breast Cancer 
Surveillance in Croatia 
Age range 
Average 
50 – 69 years old  
Dates of Recruitment 2006 – 2009  Duration of follow-up 1 year  
 
Breast Tissue Composition  OR for in situ and invasive breast cancer (95% CI) 
Adjusted for age 
Almost entirely fat Referent  
Scattered fibroglandular densities 1.66 (1.27 – 2.18) 












Selection: Study participants were recruited by active invitation to participate in screening 
program. The authors do not provide details about the method of invitation (i.e. mail, telephone, 
or mass media) or about the number of invites and/or attempted extended and percentage 
fulfilled.  
 Comparability of groups: Women in the four breast tissue composition categories differed with 
respect to age, body mass index (BMI), family history, history of breast procedure, and use of 
postmenopausal hormonal therapy among other variables. Women with ‘almost entirely fat’ 
breast tissue were older and had higher BMI’s. A higher proportion of women with ‘extremely 
dense’ breast had significant family history and history of prior breast procedures, and were 
currently taking hormone therapy.  
Follow-up: There is no information about whether outcome information was available on all 






Exposure: Breast density assessment performed by radiologist using “double blind” readings. 
This methodology increases the reliability of the measurement.  
Outcome: Data on cancer diagnosis came from pathology facilities and the registry. Only screen-
detected cancers were documented. Women with interval cancers were excluded from the 
analysis. There was no procedure, such as review of medical records, to confirm that non-cases 





Confounding There is appropriate attention to potential confounders with subsequent adjustment in analysis  Low potential 
for confounding 
Analysis Women with ‘scattered fibroglandular densities’ and ‘heterogeneously dense’ breast tissue 





 The method of active invitation likely selects for participants with certain characteristics that may 




The study was conducted in Croatia, limiting its applicability to the general US population. The 
assessment of the exposure also entailed a procedure, double-blind reading, which is not 






Table 15. Data Extraction Table for Tice et al. 200558 
 
Study Design Model development Sample size for analysis 81,777 




35 years or older 
55.9 
Dates of Recruitment 1993 – 2002  Average follow-up time 5.1 
 
Breast Tissue Composition RR of in situ and invasive breast 
cancer (95% CI) 
Adjusted for age and ethnicity 
Almost entirely fat 0.59 (0.36 – 0.98) 
Scattered fibroglandular densities Referent 
Heterogeneously dense 1.41 (1.11 – 1.78) 











Selection: The women included in this study were part of the San Francisco Mammography 
Registry, which is part of the BCSC. The eighteen participating radiology facilities include 
hospital-based facilities (N=14), clinic based practices and a mobile clinic (N=1). Only one of the 
facilities is affiliated with an academic institution. Women of unknown race/ethnicity were 
excluded from analysis. Authors did not report what proportion of the initially selected 
participants was excluded from analysis.  
Comparability of groups: They did not provide baseline characteristics of highlight differences in 
participants organized according to breast composition category. Instead, characteristics are 
given for the overall population.  
Follow-up: There were no methods detailed for confirming cancer-free status, such as mail 






Exposure: Investigators used the ACR BI-RADS breast tissue composition assessment routinely 
used by radiologists in clinical practice. The ordinal scale is inherently unequally applied and 
unreliable due to its subjectivity.  
Outcome: Breast cancer outcomes (in situ and invasive) were obtained from SEER. Vital Status 





Confounding In the analysis, adjustments were made for race and ethnicity. Other variables have been cited 
as confounding the relationship between exposure and incidence that are not accounted for in 





Analysis The risk factors were categorized according to the methods used for the Gail model. Dummy 
variables were used for missing values.  Investigators used the Cox proportional hazards model 





Validity is threatened by presence of selection and inherent measurement biases. In addition, 




One of the highlights form this study is the racially and ethnically diverse study population. In 
addition, there is variety in type of participating radiology facilities.  
Good external  
! 17 
 
Table 17. Data Extraction Table for Tice et al. 200847  
 
Study Design Modeling  Sample size for analysis 1,095,484 
Registry Seven BCSC mammography registries, which included the 
San Francisco Mammography Registry, Group Health’s 
Breast Cancer Surveillance, Colorado Mammography 
Advocacy Project, Vermont Breast Cancer Surveillance 
System, New Hampshire Mammography Network, 
Carolina Mammography Registry, and New Mexico 
Mammography Registry. 
Age range 35 years or older 
Dates of 
Recruitment 
Not reported  Average follow-up time 5.3 years 
 
Age Breast Tissue 
Composition 
5-year risk of invasive 
breast cancer 
Age Breast Tissue 
Composition 
5-year risk of invasive 
breast cancer 













































Selection: Investigators identified all women that had at least one mammogram documented in 
one of the seven registry sites. Women that had a personal history of breast cancer or a 
diagnosis within 6 months of enrollment were excluded. Other exclusion criteria included history 
of breast augmentation and diagnosis of DCIS.  
Comparability of groups: They did not provide baseline characteristics of highlight differences in 
participants organized according to breast composition category. Instead, characteristics are 
given for the overall population.  
Follow-up: There were no methods detailed for confirming cancer-free status, such as mail 






Exposure: Investigators used the ACR BI-RADS breast tissue composition assessment routinely 
used by radiologists in clinical practice. The ordinal scale is inherently unequally applied and 
unreliable due to its subjectivity.  
Outcome: Breast cancer outcomes (in situ and invasive) were obtained from SEER, state tumor 
registries and pathology databases. Vital status was obtained from state vital statistics or 





Confounding In the analysis, adjustments were made for race and ethnicity. Other variables have been cited 




Analysis Women who were diagnosed with in situ breast cancer were censored at the time of diagnosis. 
Study investigators used the proportional hazards model adjusted for age and race/ethnicity. 
Age-specific incidence for Native Americans’ and Alaskan Native women was inconsistent with 
SEER, so, they were excluded from analysis. The model was developed using a random sample 





There are meaningful issues of both selection and measurement bias. Appropriate adjustment 




The generalizability to Native American and Alaskan Native women is threatened because this 




Table 19. Data Extraction Table for Vacek et al. 200448  
 
Study Design Prospective cohort Sample size for 
analysis 
61,844 
Registry Vermont Breast Cancer Surveillance System, 
part of BCSC 
Age range 20 – 74  
Dates of 
Recruitment 
1996 - 2000 Average follow-
up time 
 3 years 
 
 Age-adjusted RR (95% CI) Age-adjusted RR (95% CI) Age-adjusted RR (95% CI) 
 All women Premenopausal Menopausal 
Entirely fat Referent Referent Referent  
Scattered fibroglandular 2.0 (1.6 – 3.0) 2.5 (1.0 – 6.7) 2.0 (1.6 – 3.0) 
Heterogeneously sense 3.0 (2.0 – 4.0) 3.7 (1.4 – 10.0) 2.8 (2.0 – 4.0) 












Selection: Eligibility criteria included having at least one mammogram documented in the registry 
during the study period and not having a self-reported or biopsy proven personal history of 
breast cancer. The date of study entry was the date of first breast density measurement.  
Comparability of groups: They did not provide baseline characteristics of highlight differences in 
participants organized according to breast composition category. Instead, characteristics are 
given for the overall population.  
Follow-up: Participants that did not receive an additional mammogram or biopsy were 
considered lost to follow-up (20,673, 24%). Those that were lost to follow-up were younger and 






Exposure: Investigators used the ACR BI-RADS breast tissue composition assessment routinely 
used by radiologists in clinical practice. The ordinal scale is inherently unequally applied and 
unreliable due to its subjectivity. BI-RADS density category documented at entry mammogram, 
which could have been at any of the participating mammography centers.  
Outcome: Information of breast cancer diagnoses collected from all the pathology facilities in VT, 
VT and NH cancer registries. The NH Cancer Registry was used because some residents of 





Confounding Baseline characteristics of the women in the four breast density categories differed in biologically 
plausible ways. A higher proportion of nulliparous and premenopausal women were categorized 
as “extremely dense” than “almost entirely fat”.    
Low 
Analysis Relationship between breast density and categorical outcome assessed by Pearson’s chi-square 
test. Age-adjusted relative risk assessed using Cox regression model with age as the time 
variable. This analysis approach accounts for aging during the study period. Effect measures 




Both the potential for selection and measurement bias are low and analysis was appropriate with 










Table 21. Data Extraction Table for Zhang et al. 201361 
 
Study Design Prospective cohort Sample size for analysis 15,243 
Registry Carolina Mammography Registry (CMR), which is 
part of the BCSC. 
Age range 30 years or older  
Dates of 
Recruitment 
1994 - 2008 Average follow-up time  3 years 
 
   Mortality probability 
at 5 years (95% CI) 
Mortality probability 
at 10 years (95% CI) 
Age 40 – 49  White Almost entirely fat/scattered 
fibroglandular 
0.05 (0.04 – 0.07) 0.09 (0.07 – 0.10) 
Heterogeneously 
dense/extremely dense 
0.04 (0.03 – 0.05) 0.06 (0.05 – 0.08)  
 African-
American 
Almost entirely fat/scattered 
fibroglandular 
0.10 (0.08 – 0.17) 0.17 (0.12 – 0.22) 
 Heterogeneously 
dense/extremely dense 
0.10 (0.06 – 0.13) 0.15 (0.10 – 0.20) 
Age 50 – 59  White Almost entirely fat/scattered 
fibroglandular  
0.05 (0.04 – 0.06) 0.08 (0.06 – 0.09) 
Heterogeneously 
dense/extremely dense 
0.04 (0.03 – 0.05) 0.07 (0.05 – 0.08) 
 African-
American 
Almost entirely fat/scattered 
fibroglandular  
0.10 (0.07 – 0.14) 0.15 (0.11 – 0.20) 
 Heterogeneously 
dense/extremely dense 










Selection: Study participants were identified from the CMR database of mammography results 
(N = 661,866). Follow-up data were linked to breast pathology database, North Carolina Central 
Cancer Registry and North Carolina State Death Tapes. A substantial proportion of the study 
population was lost to follow-up because registry and mortality outcomes could not be linked.  
Comparability of groups: They did not provide baseline characteristics of highlight differences in 
participants organized according to breast composition category. Instead, characteristics are 
given for the overall population.  
Follow-up: Information was only available for about 3.5% of the women identified in the 
mammography database. There is no documentation of how those that were lost to follow-up 






Exposure: Investigators used the ACR BI-RADS breast tissue composition assessment routinely 
used by radiologists in clinical practice. The ordinal scale is inherently unequally applied and 
unreliable due to its subjectivity. BI-RADS density category documented at entry mammogram, 
which could have been at any of the participating mammography centers.  
Outcome: Breast cancer diagnoses identified using pathology database and state registry. There 
is no mention of efforts to confirm the absence of the outcome, for example, using subsequent 
screening mammography results for non-cases. Mortality outcomes were identified using state 





Confounding Stratification used to control for age, one of the strongest risk factors for breast cancer. Race 
was another strata used in the study given aim was to identify differences breast cancer risk 
between African-American and Caucasian women.  
Appropriate  
Analysis Cause-specific cox proportional hazards model to analyze the effect of breast density on breast 
cancer mortality. They used a stratified Cox model that controlled for age and race. Cumulative 





There is a high potential for selection bias in this study, but analysis was appropriate.  Fair  
External  The study was limited to participants of certain racial groups.  Poor 
